Pipeline
Kawin continues to develop innovative products in various therapeutic areas.
Therapeutic Products
| Therapeutic Area | Project | Drug Type | Clinical Development | Market |
|---|---|---|---|---|
| Viral Hepatitis and Immunoregulation | Interferon α-2 | Long-acting interferon |
|
SEA 2026/2027 |
| BY802 | Antibody delivery | 2025/2026 | ||
| Metabolic Diseases | BY863 | GLP-1R dual agonist | 2027/2028 | |
| BY865 | GLP-1R dual agonist | 2027/2028 | ||
| Oncology | BY832 | Antibody delivery | 2026/2027 | |
| BY836 | Antibody delivery | 2028/2029 | ||
| BY839 | Bispecific antibody | 2027/2028 |
